Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer

发表于 2026-8-6 19:57:12

期刊：Therapeutic Advances in Medical Oncology

文献作者：Nicole O. Williams; Dionisia Quiroga; Courtney Johnson; Adam Brufsky; Mara Chambers; Saveri Bhattacharya; Maria Patterson; Sagar D. Sardesai; Daniel Stover; Maryam Lustberg; Anne M. Noonan; Mathew Cherian; Darlene M. Bystry; Kasey L. Hill; Min Chen; Mitch A. Phelps; Michael Grever; Julie A. Stephens; Bhuvaneswari Ramaswamy; William E. Carson; Robert Wesolowski

出版日期：2023-1-

DOI号：10.1177/17588359231217976

下载链接：https://journals.sagepub.com/doi/pdf/10.1177/17588359231217976

文献链接：https://doi.org/10.1177/17588359231217976

当前文献来源于 SAGE Publications。

备注信息：

发表于 2026-8-6 19:57:13

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[Sage] Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[Sage] Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer 一键复制